Results 131 to 140 of about 57,669 (284)
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4860-4875, June 2026.ABSTRACT Background Artificial intelligence is emerging in healthcare systems. In type 1 diabetes, AI‐enabled tools are increasingly used to support nutrition assessment and insulin decision‐making, yet their clinical utility and safety remain unclear. Methods The study aims to identify and map the evidence on the clinical utility of AI‐based diabetes ...
Yucen Wu +4 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4610-4618, June 2026.ABSTRACT Aims In China, information on individuals who test positive for islet autoantibodies (IAb), including single IAb‐positive individuals and those with early‐stage Type 1 diabetes (T1D), and their risk of progression to Stage 3 T1D is limited. The goal of this study is to assess the risk of progression to T1D in first‐degree relatives (FDRs) of ...
Lixin Guo +14 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5091-5100, June 2026.ABSTRACT Aims Studies evaluating automated insulin delivery (AID) in type 2 diabetes are limited in number and often conducted in small cohorts. We aimed to summarize efficacy and safety data through a systematic review and meta‐analysis. Materials and Methods We searched MEDLINE, PubMed, Web of Science, and CENTRAL databases and performed hand ...
Sergio Di Molfetta +7 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley +1 more source
High molecular thyrotrophin ("big"-TSH) from human pituitaries : Preparation and partial characterization [PDF]
, 1977 Erhardt, F., Scriba, Peter Christian
core +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 5217-5228, June 2026.ABSTRACT Aims There is ongoing uncertainty about whether initiating sodium–glucose co‐transporter 2 inhibitor (SGLT‐2i) therapy in individuals with type 2 diabetes (T2D) who have elevated baseline HbA1c levels may lead to an additive or potentially synergistic increase in the risk of diabetic ketoacidosis (DKA). This systematic review and meta‐analysis
Samuel Seidu +3 more
wiley +1 more source
The FASEB Journal, Volume 40, Issue 9, 15 May 2026.Three weeks of fasting‐mimicking diet in female C57BL/6J mice increased pancreatic BNR4+ cells, PDX1+BRN4+ cells and insulin+glucagon+ cells after fasting in fluorescent multiplexed immunohistochemistry. Mice showed impaired glucose tolerance after fasting but not after refeeding after 2 weeks.
Clemens M. Harer +13 more
wiley +1 more source
Acute Systemic Complications Following High‐Dose Semaglutide Reinitiation in an Elderly Patient
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Severe gastrointestinal intolerance with systemic complications can occur within hours of reinitiating high‐dose semaglutide after a prolonged treatment interruption, even in patients who previously tolerated the medication. Elderly patients with comorbidities may be particularly vulnerable.
Jay Mehta, Brent Tai, Johnathan Frunzi
wiley +1 more source
Acromegaly Presenting as Diabetic Ketoacidosis: Thinking Beyond Diabetes Mellitus [PDF]
, 2014 Farhoud, Mahmoud +2 more
core +2 more sources